MCID: RTN017
MIFTS: 60

Retinal Detachment

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Retinal Detachment

MalaCards integrated aliases for Retinal Detachment:

Name: Retinal Detachment 56 12 29 54 6 42 43 15 17 71
Retinal Detachments 15

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
retinal detachment:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:5327
OMIM 56 180050
ICD9CM 34 361.9
MeSH 43 D012163
NCIt 49 C26874
SNOMED-CT 67 42059000
ICD10 32 H33.0 H33.2
MedGen 41 C0035305
SNOMED-CT via HPO 68 263681008
UMLS 71 C0035305

Summaries for Retinal Detachment

MedlinePlus : 42 The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. It provides the sharp, central vision needed for reading, driving, and seeing fine detail. A retinal detachment lifts or pulls the retina from its normal position. It can occur at any age, but it is more common in people over age 40. It affects men more than women and whites more than African Americans. A retinal detachment is also more likely to occur in people who Are extremely nearsighted Have had a retinal detachment in the other eye Have a family history of retinal detachment Have had cataract surgery Have other eye diseases or disorders Have had an eye injury Symptoms include an increase in the number of floaters, which are little "cobwebs" or specks that float about in your field of vision, and/or light flashes in the eye. It may also seem like there is a "curtain" over your field of vision. A retinal detachment is a medical emergency. If not promptly treated, it can cause permanent vision loss. If you have any symptoms, see an eye care professional immediately. Treatment includes different types of surgery. NIH: National Eye Institute

MalaCards based summary : Retinal Detachment, also known as retinal detachments, is related to persistent hyperplastic primary vitreous, autosomal recessive and vitreoretinal degeneration. An important gene associated with Retinal Detachment is RHO (Rhodopsin), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Ketorolac and Propofol have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are retinal detachment and cardiovascular system

OMIM : 56 Primary or spontaneous detachment of the retina occurs due to underlying ocular disease and often involves the vitreous as well as the retina. The precipitating event is formation of a retinal tear or hole, which permits fluid to accumulate under the sensory layers of the retina and creates an intraretinal cleavage that destroys the neurosensory process of visual reception. Vitreoretinal degeneration and tear formation are painless phenomena, and in most cases, significant vitreoretinal pathology is found only after detachment of the retina starts to cause loss of vision or visual field. Without surgical intervention, retinal detachment will almost inevitably lead to total blindness (summary by McNiel and McPherson, 1971). (180050)

Wikipedia : 74 Retinal detachment is a disorder of the eye in which the retina separates from the layer underneath.... more...

Related Diseases for Retinal Detachment

Diseases related to Retinal Detachment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 645)
# Related Disease Score Top Affiliating Genes
1 persistent hyperplastic primary vitreous, autosomal recessive 34.0 TSPAN12 ATOH7
2 vitreoretinal degeneration 33.1 COL2A1 COL18A1 COL11A1
3 persistent hyperplastic primary vitreous 33.1 TSPAN12 NDP LRP5 FZD4 ATOH7
4 vitreoretinopathy, neovascular inflammatory 33.1 VEGFA GLUL GFAP
5 exudative vitreoretinopathy 32.9 ZNF408 TSPAN12 NDP LRP5 FZD4 CTNNB1
6 stickler syndrome, type ii 32.6 COL2A1 COL11A1
7 myopia 32.5 VEGFA SERPINF1 RHO COL2A1 COL18A1 COL11A1
8 microphthalmia 32.5 SERPINF1 NDP LRP5 CTNNB1 ATOH7
9 coats disease 32.5 ZNF408 VEGFA TSPAN12 RS1 RHO NDP
10 microvascular complications of diabetes 5 32.4 VEGFA SERPINF1 RHO PDGFB
11 vitreoretinopathy 32.1 ZNF408 TSPAN12 NDP LRP5 FZD4 CTNNB1
12 exudative vitreoretinopathy 1 32.1 ZNF408 VEGFA TSPAN12 SERPINF1 RHO NDP
13 macular holes 32.0 VEGFA SERPINF1 RS1
14 retinal perforation 31.9 VEGFA RS1 COL2A1 COL11A1
15 macular retinal edema 31.5 VEGFA SERPINF1 RHO
16 strabismus 31.4 RS1 RHO CTNNB1 COL2A1 COL11A1
17 microvascular complications of diabetes 1 31.2 VEGFA SERPINF1 GFAP
18 cataract 31.2 VEGFA SERPINF1 RHO COL2A1 COL18A1 COL11A1
19 retinal degeneration 30.9 SERPINF1 RS1 RHO GFAP COL2A1
20 vitreoretinal dystrophy 30.8 RS1 COL11A1
21 peripheral retinal degeneration 30.8 ZNF408 TSPAN12 RHO COL2A1
22 chorioretinal scar 30.8 VEGFA RHO
23 vitreous syneresis 30.8 COL2A1 COL11A1
24 osteoporosis-pseudoglioma syndrome 30.7 NDP LRP5 FZD4 CTNNB1
25 retinal telangiectasia 30.7 VEGFA TSPAN12 NDP FZD4
26 leukocoria 30.7 ZNF408 TSPAN12 NDP LRP5 FZD4
27 brittle bone disorder 30.6 SERPINF1 LRP5 COL2A1
28 norrie disease 30.6 ZNF408 TSPAN12 NDP LRP5 FZD4 CTNNB1
29 marshall syndrome 30.5 COL2A1 COL11A1
30 bullous retinoschisis 30.4 VEGFA RS1
31 macular degeneration, age-related, 1 30.4 VEGFA SERPINF1 RS1 RHO GFAP COL18A1
32 osteoporosis 30.4 VEGFA NDP LRP5 FZD4 CTNNB1 COL2A1
33 preretinal fibrosis 30.4 VEGFA GFAP
34 retinal vascular disease 30.3 ZNF408 VEGFA TSPAN12 SERPINF1 RHO NDP
35 eales disease 30.3 VEGFA SERPINF1
36 eye disease 30.2 VEGFA SERPINF1 RS1 RHO NDP GFAP
37 kuhnt-junius degeneration 30.0 VEGFA SERPINF1 COL18A1
38 brain edema 29.8 VEGFA GLUL GFAP
39 retinitis pigmentosa 29.7 ZNF408 VEGFA SERPINF1 RS1 RHO GLUL
40 leber congenital amaurosis 29.6 SERPINF1 RS1 RHO LRP5 GFAP
41 lattice degeneration of retina leading to retinal detachment 12.5
42 stickler syndrome, type i, nonsyndromic ocular 12.5
43 diverticulosis of bowel, hernia, and retinal detachment 12.4
44 knobloch syndrome 12.3
45 knobloch syndrome 1 12.1
46 retinoschisis 1, x-linked, juvenile 11.9
47 stickler syndrome 11.8
48 kniest dysplasia 11.7
49 wagner syndrome 11.7
50 spondyloocular syndrome 11.6

Comorbidity relations with Retinal Detachment via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Retinal Detachment:



Diseases related to Retinal Detachment

Symptoms & Phenotypes for Retinal Detachment

Human phenotypes related to Retinal Detachment:

31
# Description HPO Frequency HPO Source Accession
1 retinal detachment 31 HP:0000541

Symptoms via clinical synopsis from OMIM:

56
Eyes:
retinal detachment
no myopia

Clinical features from OMIM:

180050

MGI Mouse Phenotypes related to Retinal Detachment:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ATOH7 COL18A1 COL2A1 CTNNB1 FZD4 GFAP
2 behavior/neurological MP:0005386 10.27 ADAMTSL4 ATOH7 COL18A1 COL2A1 CTNNB1 FZD4
3 nervous system MP:0003631 10.27 ATOH7 COL11A1 COL18A1 COL2A1 CTNNB1 FZD4
4 digestive/alimentary MP:0005381 10.03 COL11A1 COL2A1 CTNNB1 FZD4 GFAP PDGFA
5 craniofacial MP:0005382 10 COL11A1 COL18A1 COL2A1 CTNNB1 LRP5 PDGFA
6 normal MP:0002873 9.97 ATOH7 COL2A1 CTNNB1 FZD4 GFAP GLUL
7 pigmentation MP:0001186 9.96 ADAMTSL4 COL18A1 CTNNB1 FZD4 LRP5 NDP
8 hearing/vestibular/ear MP:0005377 9.88 COL11A1 COL2A1 CTNNB1 FZD4 NDP TSPAN12
9 renal/urinary system MP:0005367 9.7 COL18A1 COL2A1 CTNNB1 FZD4 PDGFA PDGFB
10 skeleton MP:0005390 9.61 COL11A1 COL18A1 COL2A1 CTNNB1 LRP5 NDP
11 vision/eye MP:0005391 9.5 ADAMTSL4 ATOH7 COL18A1 COL2A1 CTNNB1 FZD4

Drugs & Therapeutics for Retinal Detachment

Drugs for Retinal Detachment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
6
Fosaprepitant Approved Phase 4 172673-20-0 219090
7
Ondansetron Approved Phase 4 99614-02-5 4595
8
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
9
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
10
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
11
Dipivefrin Approved Phase 4 52365-63-6 3105
12
Rasagiline Approved Phase 4 136236-51-6 3052776
13
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
14 Sodium Channel Blockers Phase 4
15 Diuretics, Potassium Sparing Phase 4
16 Ketorolac Tromethamine Phase 4
17 Tranquilizing Agents Phase 4
18 Psychotropic Drugs Phase 4
19 Anti-Anxiety Agents Phase 4
20 Antineoplastic Agents, Immunological Phase 4
21 Anesthetics, Local Phase 4
22 Immunoglobulin G Phase 4
23 Antipsychotic Agents Phase 4
24 Neurokinin-1 Receptor Antagonists Phase 4
25 neurokinin A Phase 4
26 Serotonin Agents Phase 4
27 Serotonin Antagonists Phase 4
28
Substance P Phase 4 33507-63-0 44359816
29 Antipruritics Phase 4
30 Mitogens Phase 4
31 Endothelial Growth Factors Phase 4
32 Anti-Inflammatory Agents, Non-Steroidal Phase 4
33 Cyclooxygenase Inhibitors Phase 4
34 Neurotransmitter Agents Phase 4
35 Anti-Arrhythmia Agents Phase 4
36 Ophthalmic Solutions Phase 4
37 Anti-Asthmatic Agents Phase 4
38 Respiratory System Agents Phase 4
39 Adjuvants, Anesthesia Phase 4
40 Muscarinic Antagonists Phase 4
41 Parasympatholytics Phase 4
42 Cholinergic Agents Phase 4
43 Cholinergic Antagonists Phase 4
44 Bronchodilator Agents Phase 4
45 Mydriatics Phase 4
46 Anesthetics Phase 4
47 Proxymetacaine Phase 4
48 Retinol palmitate Phase 4
49 retinol Phase 4
50 Protective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 304)
# Name Status NCT ID Phase Drugs
1 Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia Unknown status NCT01417572 Phase 4 lidocaine
2 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
3 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
4 On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD. Unknown status NCT01670162 Phase 4 Aflibercept
5 Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
6 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
7 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma: a Randomized Clinical Trial. Unknown status NCT01494974 Phase 4
8 New Horizons in the Treatment of Vitreous Floaters: Efficacy and Safety of Vitreolysis With the Ultra Q Reflex YAG Laser (Ellex) Unknown status NCT02812004 Phase 4
9 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
10 Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4 Isotretinoin
11 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
12 Open Label Study: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment. Completed NCT01722656 Phase 4 Aflibercept
13 Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration Completed NCT00976222 Phase 4 intravitreal injection with ranibizumab
14 The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
15 Evaluating the Safety and Efficacy of Polyglycolic Acid Suture in Ophthalmic Surgical Procedures Completed NCT00351429 Phase 4
16 A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration Completed NCT02142296 Phase 4 Eylea
17 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
18 Preoperative Ketorolac for Intraoperative and Postoperative Pain Management in Scleral Buckling Surgery Under Retrobulbar Block Anesthesia: A Prospective, Randomized, Controlled Study Completed NCT02729285 Phase 4 Ketorolac Tromethamine;placebo
19 Comparison of Dexmedetomidine vs. Propofol in Vitreoretinal Surgery Under Sub-Tenon's Block Completed NCT01001429 Phase 4 Dexmedetomidine infusion;propofol
20 Evaluation on Efficacy of Topical Nepafenac as Supplement Therapy in the Treatment of Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
21 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
22 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. Completed NCT00500396 Phase 4
23 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V Completed NCT00563121 Phase 4
24 Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography Completed NCT03246152 Phase 4 Bevacizumab
25 A Comparison of Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients Completed NCT00738621 Phase 4 Aprepitant, Dexamethasone, Ondansetron;Aprepitant, Dexamethasone, Placebo
26 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
27 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
28 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Recruiting NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
29 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Recruiting NCT03506750 Phase 4 IVC
30 Atropine for Children and Adolescent Myopia Progression Study (ACAMP) Enrolling by invitation NCT03949101 Phase 4 Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop;atropine 0.01% eye drop
31 Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery Not yet recruiting NCT02917564 Phase 4 Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
32 Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment Terminated NCT02068625 Phase 4 Rasagiline;Placebo
33 Effect of Dexamethasone on Postoperative Symptoms of Scleral Buckling Surgery Patients: a Randomized Control Trial Withdrawn NCT01326585 Phase 4 Dexamethasone Sodium Phosphate Injection;Saline Injection
34 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy. Withdrawn NCT01666236 Phase 4
35 This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg Withdrawn NCT01495208 Phase 4 Aflibercept
36 Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
37 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
38 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
39 Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment Unknown status NCT00404209 Phase 3
40 Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy Unknown status NCT00407108 Phase 3
41 Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR) Unknown status NCT00370721 Phase 3 bevacizumab
42 25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients Unknown status NCT02328118 Phase 2, Phase 3 Ranibizumab;Triamcinolone Acetonide
43 The Early Treatment for Retinopathy of Prematurity Study (ETROP) Unknown status NCT00027222 Phase 2, Phase 3
44 A Trial of Bifocals in Myopic Children With Esophoria Unknown status NCT00000128 Phase 3
45 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
46 Comparison of Air and Expansile Gas in Pneumatic Retinopexy Completed NCT00120445 Phase 3
47 Randomized Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation for Retinopexy in Scleral Buckle Surgery Completed NCT01068379 Phase 3
48 Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Completed NCT00373282 Phase 3 Triamcinolone acetonide
49 Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis. Completed NCT01768078 Phase 3
50 Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy: Results of the Pan-American Collaborative Retina Study (PACORES) Group Completed NCT01976923 Phase 3 Intravitreal bevacizumab

Search NIH Clinical Center for Retinal Detachment

Cochrane evidence based reviews: retinal detachment

Genetic Tests for Retinal Detachment

Genetic tests related to Retinal Detachment:

# Genetic test Affiliating Genes
1 Retinal Detachment 29

Anatomical Context for Retinal Detachment

MalaCards organs/tissues related to Retinal Detachment:

40
Eye, Retina, Endothelial, Testes, Brain, Bone, Breast

Publications for Retinal Detachment

Articles related to Retinal Detachment:

(show top 50) (show all 18124)
# Title Authors PMID Year
1
Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. 54 61
20465445 2010
2
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. 54 61
19643496 2009
3
The effects of transient retinal detachment on cavity size and glial and neural remodeling in a mouse model of X-linked retinoschisis. 61 54
19387072 2009
4
Resolution of persistent exudative retinal detachment in a case of Sturge-Weber syndrome with anti-VEGF administration. 61 54
19657986 2009
5
Upregulation of Semaphorin 3A and the associated biochemical and cellular events in a rat model of retinal detachment. 54 61
18815803 2009
6
Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis. 54 61
19668494 2007
7
Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. 61 54
16679807 2006
8
Detection of PEDF in subretinal fluid of retinal detachment: possible role in the prevention of subretinal neovascularization. preliminary results. 61 54
16679806 2006
9
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. 61 54
15635051 2005
10
High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. 61 54
15505063 2004
11
A case of Kniest dysplasia with retinal detachment and the mutation analysis. 54 61
14644246 2003
12
Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity. 61 54
14507768 2003
13
Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). 54 61
12845559 2003
14
Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. 54 61
12670875 2003
15
Up-regulation of glial fibrillary acidic protein in response to retinal injury: its potential role in glial remodeling and a comparison to vimentin expression. 54 61
14692684 2003
16
Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. 61 54
12208248 2002
17
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. 61 54
11914216 2002
18
Levels of basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in subretinal fluid from patients with retinal detachment. 61 54
11589877 2001
19
Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. 54 61
11264138 2001
20
Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. 61 54
11110038 2000
21
Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. 61 54
10980138 2000
22
Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. 61 54
11148602 2000
23
Fibrinolytic activity of subretinal fluid after cryopexy. 54 61
10651193 1999
24
Elevated vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. 61 54
12579655 1999
25
Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. 54 61
10067974 1999
26
Ocular complications and a new surgical approach to lens dislocation in homocystinuria due to cystathionine-beta-synthetase deficiency. 61 54
9587034 1998
27
Vascular endothelial growth factor upregulation in human central retinal vein occlusion. 54 61
9499769 1998
28
[Concentration of vascular endothelial growth factor within the subretinal space and vitreous fluid in rhegmatogenous retinal detachment]. 61 54
9209137 1997
29
[Biological activity of subretinal fluid in selected in vitro tests]. 54 61
9685781 1997
30
Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. 54 61
7485392 1995
31
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 61 54
7540233 1995
32
Glial fibrillary acidic protein and its mRNA: ultrastructural detection and determination of changes after CNS injury. 61 54
1486005 1992
33
Cytokines in proliferative vitreoretinopathy. 54 61
1800167 1991
34
Is there a relationship between dopamine and rhegmatogenous retinal detachment? 61
31552904 2020
35
The role of pars plana vitrectomy in the management of fungal endogenous endophthalmitis. 61
30474397 2020
36
Trans-scleral posterior capsulorhexis in combined lens extraction and silicone oil removal. 61
30871372 2020
37
Using the Retrobulbar Spot Sign to Assist in Diagnosis and Management of Central Retinal Artery Occlusions. 61
31228289 2020
38
ARTEFACTUALLY DAMPENED FLASH STIMULUS VISUAL EVOKED RESPONSES IN A SILICONE OIL-FILLED EYE. 61
28827497 2020
39
CASE REPORT OF SEVERE PROLIFERATIVE RETINOPATHY IN A PATIENT WITH CONGENITAL LIPODYSTROPHY. 61
28834920 2020
40
Fluid viscosity but not surface tension, determines the tamponade effect of intravitreal fluids in a novel in vitro eye model of retinal detachment. 61
31577983 2020
41
MACULAR HOLE IN A YOUNG PATIENT AFFECTED BY FAMILIAL EXUDATIVE VITREORETINOPATHY. 61
28850050 2020
42
Safety of 6000 intravitreal dexamethasone implants. 61
31040132 2020
43
Silicone Oil Tamponade in Rhegmatogenous Retinal Detachment: Functional and Morphological Results. 61
31478404 2020
44
Risk factors and outcomes of management of delayed suprachoroidal haemorrhage following Ahmed glaucoma valve implantation in children. 61
30923133 2020
45
Doubles trouble-85 cases of ocular trauma in badminton: clinical features and prevention. 61
30988018 2020
46
Autologous translocation of the choroid and retina pigment epitelial cells(RPE) in age-related macular degeneration: Monitoring the viability of choroid and RPE patch with indocyanine green angiography(ICGA) and fundus autofluorescence(FAF). 61
31454718 2019
47
Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography. 61
31529324 2019
48
DEVELOPMENT OF MACULAR ATROPHY AFTER PARS PLANA VITRECTOMY FOR MYOPIC TRACTION MACULOPATHY AND MACULAR HOLE RETINAL DETACHMENT IN PATHOLOGIC MYOPIA. 61
31834131 2019
49
Bilateral serous retinal detachment associated with subretinal fibrin-like material in a case of pregnancy-induced hypertension. 61
31788578 2019
50
Multicenter survey of sutureless 27-gauge vitrectomy for primary rhegmatogenous retinal detachment: a consecutive series of 410 cases. 61
31478083 2019

Variations for Retinal Detachment

ClinVar genetic disease variations for Retinal Detachment:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RHO NM_000539.3(RHO):c.891C>G (p.Ser297Arg)SNV Pathogenic 523376 rs142285818 3:129251570-129251570 3:129532727-129532727
2 NDP NM_000266.4(NDP):c.308_311dup (p.Lys104fs)duplication Likely pathogenic 523342 rs1555976049 X:43809136-43809139 X:43949890-43949893
3 EYS NM_001142800.2(EYS):c.4152del (p.Pro1385fs)deletion Uncertain significance 523414 rs1185686653 6:65301608-65301608 6:64591715-64591715

Expression for Retinal Detachment

Search GEO for disease gene expression data for Retinal Detachment.

Pathways for Retinal Detachment

Pathways related to Retinal Detachment according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 VEGFA PDGFB PDGFA LRP5 FZD4 CTNNB1
2
Show member pathways
12.79 VEGFA PDGFB PDGFA FZD4 CTNNB1 COL2A1
3
Show member pathways
12.55 PDGFB PDGFA COL2A1 COL18A1 COL11A1
4 12.46 VEGFA PDGFB PDGFA LRP5 FZD4 CTNNB1
5
Show member pathways
12.34 SERPINF1 LRP5 FZD4 CTNNB1
6
Show member pathways
12.27 PDGFB PDGFA FZD4 CTNNB1
7 11.98 VEGFA LRP5 FZD4 CTNNB1
8
Show member pathways
11.93 VEGFA RHO PDGFB PDGFA CTNNB1 COL2A1
9 11.81 VEGFA PDGFB PDGFA CTNNB1
10 11.72 GFAP CTNNB1 COL2A1
11 11.5 PDGFB PDGFA FZD4 CTNNB1
12 11.29 VEGFA PDGFB PDGFA
13 11.21 VEGFA PDGFB PDGFA
14 11.15 VEGFA PDGFB PDGFA GFAP
15 10.7 PDGFB PDGFA GFAP COL2A1 COL18A1 COL11A1

GO Terms for Retinal Detachment

Cellular components related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 VEGFA SERPINF1 RS1 PDGFB PDGFA NDP
2 extracellular region GO:0005576 9.96 VEGFA SERPINF1 RS1 PDGFB PDGFA NDP
3 basement membrane GO:0005604 9.65 SERPINF1 COL2A1 COL18A1
4 collagen trimer GO:0005581 9.63 COL2A1 COL18A1 COL11A1
5 extracellular matrix GO:0031012 9.55 VEGFA COL2A1 COL18A1 COL11A1 ADAMTSL4
6 platelet alpha granule lumen GO:0031093 9.54 VEGFA PDGFB PDGFA
7 Wnt signalosome GO:1990909 9.43 LRP5 CTNNB1
8 endoplasmic reticulum lumen GO:0005788 9.43 PDGFB PDGFA COL2A1 COL18A1 COL11A1 ADAMTSL4
9 glial cell projection GO:0097386 9.4 GLUL GFAP
10 collagen-containing extracellular matrix GO:0062023 9.17 SERPINF1 PDGFB NDP COL2A1 COL18A1 COL11A1

Biological processes related to Retinal Detachment according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.03 VEGFA RS1 PDGFB PDGFA LRP5 LDB2
2 positive regulation of cell proliferation GO:0008284 9.97 VEGFA PDGFB PDGFA LRP5 CTNNB1 COL18A1
3 negative regulation of gene expression GO:0010629 9.91 VEGFA SERPINF1 PDGFB CTNNB1
4 positive regulation of cell migration GO:0030335 9.91 VEGFA PDGFB PDGFA COL18A1
5 response to wounding GO:0009611 9.77 PDGFB PDGFA GFAP
6 angiogenesis GO:0001525 9.77 VEGFA TSPAN12 PDGFA GLUL COL18A1
7 canonical Wnt signaling pathway GO:0060070 9.76 LRP5 FZD4 CTNNB1
8 positive regulation of MAP kinase activity GO:0043406 9.74 VEGFA PDGFB PDGFA
9 vasculogenesis GO:0001570 9.73 VEGFA FZD4 CTNNB1
10 heart morphogenesis GO:0003007 9.7 VEGFA COL2A1 COL11A1
11 positive regulation of cell division GO:0051781 9.69 VEGFA PDGFB PDGFA
12 Wnt signaling pathway GO:0016055 9.65 TSPAN12 NDP LRP5 FZD4 CTNNB1
13 visual perception GO:0007601 9.63 RS1 RHO NDP COL2A1 COL18A1 COL11A1
14 negative regulation of platelet activation GO:0010544 9.59 PDGFB PDGFA
15 proteoglycan metabolic process GO:0006029 9.58 COL2A1 COL11A1
16 retinal blood vessel morphogenesis GO:0061304 9.55 LRP5 FZD4
17 retina vasculature morphogenesis in camera-type eye GO:0061299 9.54 NDP FZD4
18 positive regulation of protein autophosphorylation GO:0031954 9.5 VEGFA PDGFB PDGFA
19 positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway GO:0035793 9.48 PDGFB PDGFA
20 extracellular matrix-cell signaling GO:0035426 9.46 NDP FZD4
21 negative regulation of phosphatidylinositol biosynthetic process GO:0010512 9.4 PDGFB PDGFA
22 positive regulation of mesenchymal cell proliferation GO:0002053 9.26 VEGFA PDGFA LRP5 CTNNB1
23 extracellular matrix organization GO:0030198 9.17 PDGFB PDGFA GFAP COL2A1 COL18A1 COL11A1

Molecular functions related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.25 ZNF408 VEGFA TSPAN12 SERPINF1 RHO PDGFB
2 extracellular matrix structural constituent conferring tensile strength GO:0030020 9.43 COL2A1 COL18A1 COL11A1
3 Wnt-activated receptor activity GO:0042813 9.33 TSPAN12 LRP5 FZD4
4 platelet-derived growth factor receptor binding GO:0005161 9.13 VEGFA PDGFB PDGFA
5 platelet-derived growth factor binding GO:0048407 8.8 PDGFB PDGFA COL2A1

Sources for Retinal Detachment

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....